Dr Eleni Efstathiou is an associate professor of cancer medicine with the University of Texas md Anderson Cancer Center. She is a world known physician scientist focused on tissue based translational research in prostate cancer. Clinically she has been one of the few physicians with practice across both sides of the atlantic with extensive experience across the spectrum of genitourinary medical oncology.
Dr Efstathiou is currently the director of the clinical research group focused on driving high impact research paired with outstanding patient care. Her goal is to combine the advantages of academia with those of private care thus offering the best possible care and treatment planning to cancer patients. Dr Efstathiou has also established and directs a very successful clinical site affiliated to MD Anderson Cancer Center within the Athens medical center. This is a site of excellence in GU oncology that beyond patient care also pursues access to cutting edge clinical research.
Her main research has been novel androgen signaling inhibition treatment as a tool to guide marker driven treatment strategies in prostate cancer and genomic and non genomic pathways of resistance. She has developed and direct two research laboratories. The Stanford Alexander tissue and derivatives laboratory that is highly specialized in tissue processing and molecular interrogation and the Eckstein laboratory that focus on the interaction with clinic and patient and collection of tissue and other research samples.
In the course of the past 9 years she developed two major clinical trial platforms, in the bone metastatic setting and locally advanced disease setting respectively and has been performing “companion” studies exploring the impact of novel therapeutic agents on the tumor microenvironment and associating with pretreatment molecular characteristics. She is currently testing and validating proposed predictive signatures and is the biomarker PI for two large phase III trial testing the advantage of combinatorial androgen signaling inhibition in advanced prostatic carcinoma. Furthermore, the two laboratories she leads are providing support for tissue based research for multiple research projects including the Prostate Spore and Moon Shot Programs. She has in parallel engaged in multiple collaborations outside her current institution.
Efstathiou is the recipient of a Young Investigator Award and a Career
Development Award by the Prostate Cancer Foundation and a PI on a PCF Challenge
Award. She is an ESMO Academy faculty member and a founding and scientific
committee member of the APCCC St Gallen Consensus meeting for Prostate Cancer.
She has currently published more than 120 manuscripts in peer reviewed
journals. Of note she is the only physician scientist to present oral
presentation of her work in 6 consecutive American Society of Clinical Oncology
annual meetings. She also served as the Chair of the genitourinary scientific
committee for European Society of Medical Oncology congress and remains a
Being among the first physician scientists to engage prospectively in prostate cancer tissue based research and to identify candidate pathways of resistance and feedback to novel treatments she is internationally considered an expert spearheading therapy development strategies in prostate cancer.